Our team is actively involved in a wide range of clinical, translational and basic investigations related to pediatric cancer, disorders of the blood, including clotting or bleeding problems, and the quality of life of children and their families undergoing severe medical conditions.
As members of the Children’s Oncology Group (COG), the Beat Childhood Cancer Consortia (BCC), and the ARISE Cancer Consortia, our team of pediatric cancer experts collaborates nationally and globally with other leaders in the field to develop solutions that improve the lives of children.
Current Clinical Trials:
- We offer multiple studies unique to Duke. Please see available studies.
Brain Tumor Clinical Trials & Support:
- Find clinical trials at Duke’s The Preston Robert Tisch Brain Tumor Center.
- For additional support, visit the Destination Hope website.
- Learn about our partner organizations: CONNECT Consortium and Pediatric Neuro-oncology Consortium (PNOC).
Research Faculty
Oncology
Areas of interest: Development and evaluation of new treatments for pediatric brain tumors.
Areas of interest: Understanding epigenetics of aggressive pediatric brain tumors and improving delivery of drugs into the brain.
Areas of interest: Improving outcomes for children diagnosed with cancer in low resource settings through local diagnostic and oncology capacity development, community engagement, and development of a psychosocial support and to better understand and address the long-term physical, cognitive, and psychosocial challenges faced by survivors of pediatric brain tumors, in order to optimize their quality of life and long-term outcomes.
Areas of interest: Pediatric and young adult oncology (special interest in sarcomas), tumor evolution in chemotherapy-resistant osteosarcoma, and development of novel treatment strategies for osteosarcoma.
Areas of interest: The study of childhood rhabdomyosarcoma, using primary cell-based, xenograft and genetically-engineered mouse models to understand the implicated signaling, genomic, and epigenomic changes and to identify potential therapeutic targets.
Areas of Interest: Understanding epigenetics of aggressive pediatric brain tumors and improving delivery of drugs into the brain.
Areas of interest: 1) Using cell and molecular biology tools and whole-organism models to unravel the cancer-driving and tumor suppressor pathways that go awry in forms of childhood cancer. 2) Exploring how normal developmental programs might be leveraged as novel therapeutic approaches in rhabdomyosarcoma, neuroblastoma, and other childhood solid tumors. 3) Helping to catalyze translational research related to children with cancer and blood disorders.
Areas of interest: Wnt Signaling and Cancer Biology; Circadian Rhythm.
Areas of interest: The study of childhood rhabdomyosarcoma, using primary cell-based, xenograft and genetically-engineered mouse models to understand the implicated signaling, genomic, and epigenomic changes and to identify potential therapeutic targets.
Areas of interest: 1) Using cell and molecular biology tools and whole-organism models to unravel the cancer-driving and tumor suppressor pathways that go awry in forms of childhood cancer. 2) Exploring how normal developmental programs might be leveraged as novel therapeutic approaches in rhabdomyosarcoma, neuroblastoma, and other childhood solid tumors. 3) Helping to catalyze translational research related to children with cancer and blood disorders.
Areas of interest: Developing umbilical cord blood-derived therapies for the treatment of childhood genetic and acquired neurologic disorders.
Hutton Chapman, MD, MS
Areas of interest: Addressing disparities in childhood cancer outcomes in low resource settings utilizing implementation science and clinical research and improving the care of survivors of childhood cancer.
Areas of interest: Improving outcomes for children diagnosed with cancer in low resource settings through local diagnostic and oncology capacity development, community engagement , and development of a psychosocial support and to better understand and address the long-term physical, cognitive, and psychosocial challenges faced by survivors of pediatric brain tumors, in order to optimize their quality of life and long-term outcomes.
Kyra McCarty, DO
Areas of interest: Understanding the epidemiology, risk factors, and prevention of chemotherapy-related toxicities in pediatric patients with leukemia.
Areas of interest: Developing umbilical cord blood-derived therapies for the treatment of childhood genetic and acquired neurologic disorders.
Areas of interest: Pediatric and young adult oncology (special interest in sarcomas), tumor evolution in chemotherapy-resistant osteosarcoma, and development of novel treatment strategies for osteosarcoma.
Areas of interest: Improving treatments for neuroblastoma patients; coordinating care for childhood cancer survivors.
Areas of interest: The study of childhood rhabdomyosarcoma, using primary cell-based, xenograft and genetically-engineered mouse models to understand the implicated signaling, genomic, and epigenomic changes and to identify potential therapeutic targets.
Areas of interest: 1) Using cell and molecular biology tools and whole-organism models to unravel the cancer-driving and tumor suppressor pathways that go awry in forms of childhood cancer. 2) Exploring how normal developmental programs might be leveraged as novel therapeutic approaches in rhabdomyosarcoma, neuroblastoma, and other childhood solid tumors. 3) Helping to catalyze translational research related to children with cancer and blood disorders.
Areas of interest: Developing umbilical cord blood-derived therapies for the treatment of childhood genetic and acquired neurologic disorders.
Areas of interest: Factors that impact sarcoma formation; clinical studies that impact oncologic sequelae of neurofibromatosis.
Hutton Chapman, MD, MS
Areas of interest: Addressing disparities in childhood cancer outcomes in low resource settings utilizing implementation science and clinical research and improving the care of survivors of childhood cancer.
Areas of interest: Improving treatments for neuroblastoma patients; coordinating care for childhood cancer survivors.
Hematology
Areas of interest: Benign hematology, including congenital hemolytic anemia, sickle cell disease, immune thrombocytopenia, aplastic anemia and bone marrow failure syndromes.
Areas of interest: Classical hematology including hemoglobinopathies, red cell disorders, platelet disorders, hemostasis and thrombosis, bleeding disorders, focusing on evaluating, diagnosing, treating, improving quality of life and advocating for adolescents with menorrhagia (heavy periods) and patients with sickle cell disease and rare bleeding disorders.
Areas of interest: Benign hematology, including congenital hemolytic anemia, sickle cell disease, immune thrombocytopenia, aplastic anemia and bone marrow failure syndromes.
Areas of interest: Benign hematology, including congenital hemolytic anemia, sickle cell disease, immune thrombocytopenia, aplastic anemia and bone marrow failure syndromes.
Areas of interest: Novel therapeutic options for patients with sickle cell disease; transition from pediatric to adult care for sickle cell disease; and use of mobile technology to advance patient care for sickle cell disease; use of wearables to provide objective data to combine with subjective symptoms in patients with sickle cell disease, cancer and bone marrow transplant who have pain.
Areas of interest: My research focuses on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials.